GlassScriptPhysician profile
William T Gonzaba
NPI 1548231905
$5,160.71
in general payments reported to CMS, 2019-2025
31 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $689 · 2021: $714 · 2022: $865 · 2023: $647 · 2024: $746 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $692.09 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.71 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $529.54 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $406.02 | 2019-2025 | |
| Amgen INC. | $206.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $167.00 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $156.73 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $155.95 | 2022-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $123.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $118.71 | 2019-2022 | |
| Pfizer INC. | $116.78 | 2019-2025 | |
| Dynavax Technologies Corporation | $110.58 | 2024-2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $105.96 | 2023-2024 | Gemtesa |
| Madrigal Pharmaceuticals | $92.56 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $89.31 | 2023-2025 | Auvelity |
| Abbvie INC. | $86.58 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.43 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $70.05 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.47 | 2024-2025 | Xifaxan |
| Genentech USA, INC. | $47.22 | 2019-2020 | |
| Amarin Pharma, INC. | $38.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.28 | 2022 | |
| Nestle Healthcare Nutrition INC. | $34.89 | 2022 | |
| Esperion Therapeutics, INC. | $34.06 | 2021 | |
| Shire North American Group INC | $32.28 | 2019 | |
| Lundbeck LLC | $22.11 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2020 | |
| Corcept Therapeutics | $18.40 | 2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $17.08 | 2025 | Ultomiris |
| Alfasigma USA, INC. | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gonzaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.